Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul;50(7):619-34.
doi: 10.1310/hpj5007-619. Epub 2015 Jul 31.

Edoxaban

Dennis J Cada  1 , Danial E Baker  2 , Kyle Ingram  3
Affiliations

Edoxaban

Dennis J Cada et al. Hosp Pharm. 2015 Jul.

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The July 2015 monograph topics are ivabradine, dinutuximab, glycopyrronium bromide/indacaterol, patriromer, and idarucizumab. The Safety MUE is on ivabradine.

PubMed Disclaimer

References

    1. Savaysa (edoxaban) [prescribing information]. Parsippany, NJ: Daiichi Sankyo Co; January 2015.
    1. Edoxaban. ClinicalTrials.gov Web site. http://www.clinicaltrials.gov Accessed February10, 2015.
    1. Fuji T, Wang C-J, Fujita S, Tachibana S, Kawai Y. Edoxaban in patients undergoing total hip arthroplasty: A phase IIb dose-finding study [abstract]. Blood. 2009;114(22):2098.
    1. Fuji T, Wang C-J, Fujita S, et al. Efficacy and safety of edoxaban for the prevention of venous thromboembolism after total knee or hip arthroplasty: A pooled analysis of two pivotal studies vs. enoxaparin [abstract]. Thromb Haemost. 2011;9(suppl 2):109.
    1. Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22): 2093–2104. - PubMed

LinkOut - more resources